PF-07245303
PF-07245303 is a ITK/TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2655556-75-3
- 화학식: C25H32N6O2
- 분자량:448.56
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
TrkA 2.94 nM (Kd) |
TrkB 8.76 nM (Kd) |
TrkC 10 nM (Kd) |
In Vitro
PF-07245303 (0.49-40 nM; 60 s association phase, 60-480 s dissociation phase) binds potently to recombinant human ITK, TRKA, TRKB and TRKC proteins, with Kd values of 0.71 nM, 2.94 nM, 8.73 nM and 10 nM, respectively[1].
PF-07245303 potently inhibits the enzymatic activity of full-length human ITK protein under the condition of 1 mM ATP, with an IC50 of 5.62 nM[1].
PF-07245303 (0-10 μM; 30 min pre-incubation, 5 min activation) potently inhibits ITK-dependent PLCγ1 phosphorylation in Jurkat T cells activated by anti-CD3/CD28, with an IC50 of 154 nM[1].
PF-07245303 potently inhibits IL-2 release from human primary CD4+ T cells activated by anti-CD3/CD28, with an IC50 of 38.5 nM[1].
PF-07245303 inhibits IL-2 release from human whole blood T cells activated by anti-CD3/CD28/CD2, with an IC50 of 1350 nM (122 nM after protein binding correction)[1].
PF-07245303 (20-24 h) inhibits the release of IL-4, IL-13, IFNγ, IL-17A and IL-10 from human primary CD4+ T cells activated by anti-CD3/CD28, with corresponding IC50 values of 73.5 nM, 348 nM, 73.2 nM, 282 nM and 114.5 nM[1].
PF-07245303 (6-7 days) inhibits cytokine release from differentiated human Th1, Th2 and Th17 cells, with IC50 values of 35.4 nM, 60.9 nM and 12.5 nM against IFNγ, IL-13 and IL-17A, respectively[1].
PF-07245303 potently inhibits IFNγ release from human primary CD8+ T cells activated by anti-CD3/CD28, with an IC50 of 18.9 nM[1].
PF-07245303 potently inhibits the enzymatic activities of the cytoplasmic domains of human TRKA, TRKB and TRKC, with mean IC50 values of 7.2 nM, 12.0 nM and 20.7 nM, respectively, under 1 mM ATP conditions[1].
PF-07245303 inhibits ligand-induced phosphorylation of human TRKA, TRKB and TRKC in U2OS cells (expressing p75), with IC50 values of 72.6 nM, 48.7 nM and 21.7 nM, respectively[1].
PF-07245303 inhibits NGF-induced activation of primary human blood basophils with an IC50 of 442 nM (39.8 nM after protein binding correction)[1].
PF-07245303 (0.1-10 μM; 24 h IL-4/IL-13 pre-treatment, 5 min NGF co-incubation) inhibits NGF-induced TRKA phosphorylation in human skin explants pre-treated with IL-4/IL-13[1].
PF-07245303 (0.3-10 μM; 24 h) inhibits anti-CD3/CD28-induced IFNG, IL13 and IL2 mRNA expression in a concentration-dependent manner, with almost complete inhibition observed at 10 μM; meanwhile, this agent also suppresses IL-2 protein release, with significant inhibitory effects detected at 1, 3 and 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat T cells (Clone E6-1)
-
Concentration:0, 0.001, 0.003, 0.01, 0.03, 0.1, 1, 3.2, 10 μM
-
Incubation Time:30 min (pre-incubation); 5 min (activation)
-
Result:Inhibited anti-CD3/CD28-induced phosphorylation of PLCγ1 in a concentration-dependent manner, with an IC50 of 154 nM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8-10 weeks of age, oxazolone-induced contact hypersensitivity model)[1]
-
Dosage:2%
-
Administration:topical; daily; starting one hour after the first oxazolone challenge, On days 4, 7, 9, and 11 after the start of oxazolone stimulation
-
Result:Inhibited oxazolone-induced ear thickness by 43% - 61% at days 4, 7, 9, and 11 after initiation of challenge.
Reduced visual and histological composite disease scores relative to vehicle treatment.
Moderately decreased ear tissue protein levels of IL-4, IL-10, IL-17A, GM-CSF, and TNFα.
Showed no difference in ear tissue protein levels of IL-2 and IFNγ compared to vehicle.
Moderately decreased scores for dermal inflammatory cell infiltrates and epithelial endpoints including hyperplasia, ulceration, thinning, and surface hyperkeratosis.
Chemical Information
-
CAS No. 2655556-75-3
-
분자량 448.56
-
화학식 C25H32N6O2
-
SMILES
CC1=C(C=C2NC(C3=NNC4=C3C[C@@H]5C[C@@]5(C4)C)=NC2=C1)N(C([C@@H](N6CCOCC6)C)=O)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)